Amicus Therapeutics Inc. Lobbying and Insider Trading Update

Amicus Therapeutics Inc. disclosed $10,000 in lobbying expenses. This report highlights a concerning trend with 6 insider sales and institutional shifts impacting $FOLD stock, raising questions for investors.

Date: 06-01-2025

AI Rating: 4

Lobbying Disclosure: Amicus Therapeutics Inc. reported $10,000 spend on lobbying efforts in Q4 2024, focusing on newborn screening and prescription drug affordability. Although this may indicate an attempt to improve their market position, the impact on stock performance is uncertain based purely on lobbying activities.

Insider Trading Activity: The absence of insider purchases (only sales were recorded) by the President and CEO, who sold 45,401 shares, is a red flag. Insider selling often signals lack of confidence in future stock performance.

Hedge Fund Activity: The report indicates mixed activity among institutional investors with 146 adding shares and 113 decreasing positions. However, notable actions include significant sales by Janus Henderson Group PLC (-52.1%) and Pictet Asset Management Holding SA (-61.4%), which reflects a declining confidence in this stock.

Such trends can negatively influence investor perceptions yet could be construed positively in light of other institutions increasing their stakes.

Stocks: FOLD